Literature DB >> 17155937

Etoricoxib pre-medication combined with intra-operative subacromial block for pain after arthroscopic acromioplasty.

J Toivonen1, V-M Pitko, P H Rosenberg.   

Abstract

BACKGROUND: Arthroscopic shoulder surgery under general anaesthesia is often associated with severe post-operative pain which may delay discharge and the start of rehabilitation. Etoricoxib is a new cyclo-oxygenase-2 inhibitor with a long duration of action and a lack of a deteriorating effect on platelet function. Therefore, the effect of pre-operative etoricoxib combined with local anaesthesia on post-operative pain and the discharge profile was studied in day-surgery patients undergoing arthroscopic shoulder surgery under general anaesthesia.
METHODS: Thirty ASA I-II adult patients scheduled for arthroscopic shoulder surgery were enrolled in this randomized prospective study. Half of the patients received etoricoxib 120 mg orally (group E) and the other half received placebo tablet orally (group C) 1 h before surgery. All patients received 20 ml of bupivacaine 2.5 mg/ml solution with epinephrine at the start of surgery and 20 ml of bupivacaine 5.0 mg/ml solution with epinephrine at the end of surgery into the subacromial space. All patients received general anaesthesia with spontaneous breathing via a laryngeal mask. In the post-anaesthesia care unit, pain was assessed on a scale from 0 to 10 (visual analogue scale, VAS) and intravenous fentanyl 25 microg was administered as scheduled (VAS > or = 3). In the day-surgery unit and at home, the analgesic was a tablet containing paracetamol 500 mg + codeine 30 mg (VAS > or = 3), as needed.
RESULTS: Patients in group E reported lower post-operative pain scores at 30, 60, 120 (P < 0.01) and 180 min (P < 0.05) after surgery, and longer time to first analgesic use (P < 0.05). Patients in group E required less fentanyl (P < 0.05) and were discharged more quickly (P < 0.05) than patients in group C. Patients in group E had a lower cumulative consumption of paracetamol + codeine tablets (P < 0.05) and lower pain scores (P < 0.05) during 7 days at home than patients in group C. Adverse events were rare in both groups.
CONCLUSION: In patients having arthroscopic shoulder surgery under general anaesthesia combined with intra-operative subacromial regional analgesia, etoricoxib 120 mg reduced immediate and late post-operative pain, and facilitated early post-operative discharge.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17155937     DOI: 10.1111/j.1399-6576.2006.01204.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  5 in total

1.  The Cerebrospinal Fluid Distribution of Postoperatively Administred Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Markers in Patients Undergoing Hip Arthroplasty.

Authors:  Annika Piirainen; Merja Kokki; Heidi Hautajärvi; Marko Lehtonen; Hannu Miettinen; Kari Pulkki; Veli-Pekka Ranta; Hannu Kokki
Journal:  Clin Drug Investig       Date:  2016-07       Impact factor: 2.859

2.  Protective multimodal analgesia with etoricoxib and spinal anesthesia in inguinal hernia repair: a randomized controlled trial.

Authors:  Mostafa Somri; Nasir Hawash; Christopher Hadjittofi; Marlain Ghantous-Toukan; Riad Tome; Marina Yodashkin; Ibrahim Matter
Journal:  J Anesth       Date:  2017-04-28       Impact factor: 2.078

3.  Impact of a Standardized Multimodal Analgesia Protocol on Opioid Prescriptions After Common Arthroscopic Procedures.

Authors:  Christina J Hajewski; Robert W Westermann; Andrew Holte; Alan Shamrock; Matthew Bollier; Brian R Wolf
Journal:  Orthop J Sports Med       Date:  2019-09-26

4.  Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery--a pilot study.

Authors:  Bertold Renner; Josef Zacher; Asokumar Buvanendran; Gerrit Walter; Jochen Strauss; Kay Brune
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-01-06       Impact factor: 3.000

5.  Preoperative administration of etoricoxib in patients undergoing hip replacement causes inhibition of inflammatory mediators and pain relief.

Authors:  B Renner; G Walter; J Strauss; M F Fromm; J Zacher; K Brune
Journal:  Eur J Pain       Date:  2011-12-19       Impact factor: 3.931

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.